Metastatic bone disease in the era of bone-targeted therapy

Clinical impact

Toni Ibrahim, Alberto Farolfi, Laura Mercatali, Marianna Ricci, Dino Amadori

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Advances in the diagnosis and treatment of tumors by surgery, chemotherapy, biotherapy, radiotherapy and other modalities have increased the survival of cancer patients over the last 20 years. As a consequence, bone now represents the third most common site of metastatic involvement after the lung and liver. Approximately 20-25% of patients with neoplastic disease develop clinically evident bone metastases (BMs) during the natural course of their illness, with a further 50% of such lesions being identified during autopsy. BMs are the major cause of morbidity in cancer patients because of their epidemiological and clinical impact. Pain is the most frequent symptom in about 75% of patients but other serious complications can also occur, such as pathological fractures, spinal cord compression, hypercalcemia and bone marrow suppression. These complications worsen the patient's general condition and reduce patients' mobility, facilitating the development of lung infections, skin ulcers, deep vein thrombosis, etc., and ultimately reducing prognosis and quality of life. The frequency of serious complications depends on the site and type of lesions and the treatment administered. Over the last 10 years, the introduction of bisphosphonates for the treatment of patients with BMs has led to a marked decrease in the frequency of complications, thus improving quality of life and clinical outcome. Furthermore, progress in understanding the pathophysiology of bone metastases has resulted in the development of new bone-targeted molecules such as denosumab. We therefore felt it would be useful to report on the epidemiological, clinical and economic impact of bone disease in a cancer setting.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalTumori
Volume99
Issue number1
DOIs
Publication statusPublished - Jan 2013

Fingerprint

Bone Diseases
Bone and Bones
Neoplasm Metastasis
Therapeutics
Neoplasms
Quality of Life
Skin Ulcer
Lung
Spontaneous Fractures
Spinal Cord Compression
Biological Therapy
Bone Development
Diphosphonates
Hypercalcemia
Venous Thrombosis
Autopsy
Radiotherapy
Bone Marrow
Economics
Morbidity

Keywords

  • Bone metastases
  • Bonetargeted therapy
  • Clinical impact
  • Skeletal-related events

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Metastatic bone disease in the era of bone-targeted therapy : Clinical impact. / Ibrahim, Toni; Farolfi, Alberto; Mercatali, Laura; Ricci, Marianna; Amadori, Dino.

In: Tumori, Vol. 99, No. 1, 01.2013, p. 1-9.

Research output: Contribution to journalArticle

Ibrahim, Toni ; Farolfi, Alberto ; Mercatali, Laura ; Ricci, Marianna ; Amadori, Dino. / Metastatic bone disease in the era of bone-targeted therapy : Clinical impact. In: Tumori. 2013 ; Vol. 99, No. 1. pp. 1-9.
@article{d385e5bdd7714aabb437e422a3fbe140,
title = "Metastatic bone disease in the era of bone-targeted therapy: Clinical impact",
abstract = "Advances in the diagnosis and treatment of tumors by surgery, chemotherapy, biotherapy, radiotherapy and other modalities have increased the survival of cancer patients over the last 20 years. As a consequence, bone now represents the third most common site of metastatic involvement after the lung and liver. Approximately 20-25{\%} of patients with neoplastic disease develop clinically evident bone metastases (BMs) during the natural course of their illness, with a further 50{\%} of such lesions being identified during autopsy. BMs are the major cause of morbidity in cancer patients because of their epidemiological and clinical impact. Pain is the most frequent symptom in about 75{\%} of patients but other serious complications can also occur, such as pathological fractures, spinal cord compression, hypercalcemia and bone marrow suppression. These complications worsen the patient's general condition and reduce patients' mobility, facilitating the development of lung infections, skin ulcers, deep vein thrombosis, etc., and ultimately reducing prognosis and quality of life. The frequency of serious complications depends on the site and type of lesions and the treatment administered. Over the last 10 years, the introduction of bisphosphonates for the treatment of patients with BMs has led to a marked decrease in the frequency of complications, thus improving quality of life and clinical outcome. Furthermore, progress in understanding the pathophysiology of bone metastases has resulted in the development of new bone-targeted molecules such as denosumab. We therefore felt it would be useful to report on the epidemiological, clinical and economic impact of bone disease in a cancer setting.",
keywords = "Bone metastases, Bonetargeted therapy, Clinical impact, Skeletal-related events",
author = "Toni Ibrahim and Alberto Farolfi and Laura Mercatali and Marianna Ricci and Dino Amadori",
year = "2013",
month = "1",
doi = "10.1700/1248.13780",
language = "English",
volume = "99",
pages = "1--9",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Metastatic bone disease in the era of bone-targeted therapy

T2 - Clinical impact

AU - Ibrahim, Toni

AU - Farolfi, Alberto

AU - Mercatali, Laura

AU - Ricci, Marianna

AU - Amadori, Dino

PY - 2013/1

Y1 - 2013/1

N2 - Advances in the diagnosis and treatment of tumors by surgery, chemotherapy, biotherapy, radiotherapy and other modalities have increased the survival of cancer patients over the last 20 years. As a consequence, bone now represents the third most common site of metastatic involvement after the lung and liver. Approximately 20-25% of patients with neoplastic disease develop clinically evident bone metastases (BMs) during the natural course of their illness, with a further 50% of such lesions being identified during autopsy. BMs are the major cause of morbidity in cancer patients because of their epidemiological and clinical impact. Pain is the most frequent symptom in about 75% of patients but other serious complications can also occur, such as pathological fractures, spinal cord compression, hypercalcemia and bone marrow suppression. These complications worsen the patient's general condition and reduce patients' mobility, facilitating the development of lung infections, skin ulcers, deep vein thrombosis, etc., and ultimately reducing prognosis and quality of life. The frequency of serious complications depends on the site and type of lesions and the treatment administered. Over the last 10 years, the introduction of bisphosphonates for the treatment of patients with BMs has led to a marked decrease in the frequency of complications, thus improving quality of life and clinical outcome. Furthermore, progress in understanding the pathophysiology of bone metastases has resulted in the development of new bone-targeted molecules such as denosumab. We therefore felt it would be useful to report on the epidemiological, clinical and economic impact of bone disease in a cancer setting.

AB - Advances in the diagnosis and treatment of tumors by surgery, chemotherapy, biotherapy, radiotherapy and other modalities have increased the survival of cancer patients over the last 20 years. As a consequence, bone now represents the third most common site of metastatic involvement after the lung and liver. Approximately 20-25% of patients with neoplastic disease develop clinically evident bone metastases (BMs) during the natural course of their illness, with a further 50% of such lesions being identified during autopsy. BMs are the major cause of morbidity in cancer patients because of their epidemiological and clinical impact. Pain is the most frequent symptom in about 75% of patients but other serious complications can also occur, such as pathological fractures, spinal cord compression, hypercalcemia and bone marrow suppression. These complications worsen the patient's general condition and reduce patients' mobility, facilitating the development of lung infections, skin ulcers, deep vein thrombosis, etc., and ultimately reducing prognosis and quality of life. The frequency of serious complications depends on the site and type of lesions and the treatment administered. Over the last 10 years, the introduction of bisphosphonates for the treatment of patients with BMs has led to a marked decrease in the frequency of complications, thus improving quality of life and clinical outcome. Furthermore, progress in understanding the pathophysiology of bone metastases has resulted in the development of new bone-targeted molecules such as denosumab. We therefore felt it would be useful to report on the epidemiological, clinical and economic impact of bone disease in a cancer setting.

KW - Bone metastases

KW - Bonetargeted therapy

KW - Clinical impact

KW - Skeletal-related events

UR - http://www.scopus.com/inward/record.url?scp=84878157835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878157835&partnerID=8YFLogxK

U2 - 10.1700/1248.13780

DO - 10.1700/1248.13780

M3 - Article

VL - 99

SP - 1

EP - 9

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 1

ER -